- Home
- MACI vs DSGN Comparison
MACI vs DSGN Comparison
Compare MACI & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MACI
- DSGN
- Stock Information
- Founded
- MACI 2024
- DSGN 2017
- Country
- MACI United States
- DSGN United States
- Employees
- MACI N/A
- DSGN N/A
- Industry
- MACI
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- MACI
- DSGN Health Care
- Exchange
- MACI NYSE
- DSGN Nasdaq
- Market Cap
- MACI 221.6M
- DSGN 224.8M
- IPO Year
- MACI 2024
- DSGN 2021
- Fundamental
- Price
- MACI $10.37
- DSGN $3.73
- Analyst Decision
- MACI
- DSGN Hold
- Analyst Count
- MACI 0
- DSGN 1
- Target Price
- MACI N/A
- DSGN $4.00
- AVG Volume (30 Days)
- MACI 9.4K
- DSGN 91.9K
- Earning Date
- MACI 01-01-0001
- DSGN 05-07-2025
- Dividend Yield
- MACI N/A
- DSGN N/A
- EPS Growth
- MACI N/A
- DSGN N/A
- EPS
- MACI 0.33
- DSGN N/A
- Revenue
- MACI N/A
- DSGN N/A
- Revenue This Year
- MACI N/A
- DSGN N/A
- Revenue Next Year
- MACI N/A
- DSGN N/A
- P/E Ratio
- MACI $31.51
- DSGN N/A
- Revenue Growth
- MACI N/A
- DSGN N/A
- 52 Week Low
- MACI $9.95
- DSGN $2.60
- 52 Week High
- MACI $10.40
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- MACI N/A
- DSGN 48.52
- Support Level
- MACI N/A
- DSGN $3.31
- Resistance Level
- MACI N/A
- DSGN $4.13
- Average True Range (ATR)
- MACI 0.00
- DSGN 0.31
- MACD
- MACI 0.00
- DSGN 0.04
- Stochastic Oscillator
- MACI 0.00
- DSGN 61.27
About MACI MELAR ACQUISITION CORP. I
Melar Acquisition Corp I is a blank check company.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.